IGC Pharma announces additional interim results from IGC-AD1 trial

IGC Pharma (IGC) announced additional interim results from its ongoing Phase 2 clinical trial on IGC-AD1, an investigational treatment for agitation in dementia due to Alzheimer’s disease. Based on the interim analysis at week 2 sleep disturbance was reduced by about 71% and at week 6 about 78% for those on the active medication. These values indicate a clinical and statistically significant reduction in sleep disturbances among Alzheimer’s patients receiving the active medication compared to placebo, as measured by the Neuropsychiatric Inventory Sleep Subscale.